Alexza Pharmaceuticals announces commercialization and development collaboration with Biovail Laboratories International Alexza Pharmaceuticals, Inc http://www.avanafilrx.com/stendra-vs-cialis.html .S. And Canada. King, Alexza President and CEO. ‘This contract provides Biovail with a promising late-stage specialty CNS product,’ said Expenses Wells, Biovail’s Chief Executive Officer. We are delighted to be partnering with Alexza to bring this important treatment to advertise.’ Related StoriesNew study compares efficiency of clozapine with standard antipsychotics in adults with schizophreniaImmune submits Bertilimumab IND application to FDA for treatment of Bullous PemphigoidLithium can be safe, effective for children experiencing bipolar disorderThe collaboration provides for the commercialization and development of AZ-004 for multiple indications, including the proposed preliminary indication of dealing with agitation in schizophrenia and bipolar sufferers, and also potential future clinical advancement in additional psychiatric and neurological indications and the symptoms associated with these indications.
Alimera Sciences begins pilot study of Iluvien intravitreal insert Alimera Sciences, Inc., a held biopharmaceutical organization that specializes in the study privately, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment offers started for a pilot study to assess the safety and efficacy of Iluvien in sufferers with macular edema secondary to retinal vein occlusion. The randomized, double-masked pilot study, named FAVOR , compares two doses of Iluvien .